{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:09:29Z","timestamp":1792606169339,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.urolonc.2022.02.014","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T17:52:57Z","timestamp":1647539577000},"page":"200.e11-200.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Effectiveness and safety of adjuvant chemotherapy compared to neoadjuvant chemotherapy in patients with penile cancer and positive lymph nodes regarding overall survival and free disease survival: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"40","author":[{"given":"Juan Fernando","family":"Paz Rojas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A","family":"Ballestas Almario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6945-8261","authenticated-orcid":false,"given":"Herney Andr\u00e9s","family":"Garc\u00eda-Perdomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2022.02.014_bib0001","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00345-011-0802-0","article-title":"Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma","volume":"31","author":"Chaux","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0002","article-title":"Cancer Incidence in five continents","volume":"10","author":"Forman","year":"2014","journal-title":"Intl Agency Res Cancer"},{"issue":"SUPPL. 3","key":"10.1016\/j.urolonc.2022.02.014_bib0003","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1468-3083.2012.04520.x","article-title":"Carcinogenic risks of Psoralen UV-A therapy and Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review","volume":"26","author":"Archier","year":"2012","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0004","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.juro.2015.12.096","article-title":"High risk human papillomavirus infection of the foreskin in asymptomatic men and patients with phimosis","volume":"195","author":"Afonso","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0005","first-page":"267","article-title":"Risk factors for penile cancer: results of a population-based case-control study in Los Angeles County (United States)","volume":"12","author":"Tseng","year":"2001","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0006","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jnci\/85.1.19","article-title":"History of circumcision, medical conditions, and sexual activity and risk of penile cancer","volume":"85","author":"Maden","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0007","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2014.10.017","article-title":"EAU guidelines on penile cancer: 2014 update","volume":"67","author":"Hakenberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0008","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ucl.2016.06.007","article-title":"Surgical advances in inguinal lymph node dissection: optimizing treatment outcomes","volume":"43","author":"Sharma","year":"2016","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0009","article-title":"EAU guidelines on penile cancer 2020","author":"Hakenberg","year":"2020","journal-title":"Eur Assoc Urol Guid"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0010","unstructured":"National Comprehensive Cancer Network. NCCN Penile Cancer Guidelines [Internet]. Vol. 1, Guidelines (Version 1.2020). 2020. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/penile.pdf"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0011","first-page":"318","article-title":"AJCC cancer staging manual, 8th edition","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0012","doi-asserted-by":"crossref","first-page":"621","DOI":"10.21037\/tau.2020.01.32","article-title":"Nomograms to predict the presence and extent of inguinal lymph node metastasis in penile cancer patients with clinically positive lymph nodes","volume":"9","author":"Zhou","year":"2020","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0013","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/sti.2009.036061","article-title":"Referrals into a dedicated British penile cancer centre and sources of possible delay","volume":"85","author":"Lucky","year":"2009","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0014","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/bju.12946","article-title":"Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy","volume":"117","author":"Dickstein","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0015","first-page":"1","year":"2011","journal-title":"Cochrane Collab"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0016","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"jan02 1","key":"10.1016\/j.urolonc.2022.02.014_bib0017","article-title":"PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist\u202f: recommended items to address in a systematic review protocol","volume":"349","author":"Liberati","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0018","unstructured":"The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhague: The Nordic Cochrane Centre;"},{"issue":"4S","key":"10.1016\/j.urolonc.2022.02.014_bib0019","first-page":"e719","article-title":"MP49-09 adjuvant chemotherapy in the treatment of lymph node positive squamous cell carcinoma of the penis: analysis of the national cancer data base","volume":"201","author":"Raup","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0020","doi-asserted-by":"crossref","first-page":"x81","DOI":"10.1093\/annonc\/mdx661.007","article-title":"Chemotherapy in carcinoma penis: experience from a tertiary cancer centre in India","volume":"28","author":"Mailankody","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0021","doi-asserted-by":"crossref","first-page":"e3617","DOI":"10.1016\/S1569-9056(19)34737-2","article-title":"Systemic anti-cancer treatment for penile cancer: real world experience of tertiary cancer centre","volume":"18","author":"Derby","year":"2019","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3346\/jkms.2018.33.e1","article-title":"Prognostic factors of penile cancer and the efficacy of adjuvant treatment after penectomy: results from a multi-institution study","volume":"33","author":"Kim","year":"2018","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0023","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.clgc.2017.02.002","article-title":"Clinical outcomes of perioperative chemotherapy in patients with locally advanced penile squamous-cell carcinoma: results of a multicenter analysis","volume":"15","author":"Necchi","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0024","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clgc.2015.07.009","article-title":"A Combination of cisplatin and 5-fluorouracil with a taxane in patients who underwent lymph node dissection for nodal metastases from squamous cell carcinoma of the penis: treatment outcome and survival analyses in neoadjuvant and adjuvant settings","volume":"14","author":"Nicolai","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0025","first-page":"496.e17","article-title":"Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study","volume":"33","author":"Sharma","year":"2015","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5847-2","article-title":"Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis","volume":"19","author":"Xu","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0027","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/0974-7796.102659","article-title":"Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer","volume":"4","author":"Noronha","year":"2012","journal-title":"Urol Ann"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0028","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","article-title":"Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: A phase II study","volume":"28","author":"Pagliaro","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0029","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/bjc.2013.620","article-title":"Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK\/09\/001)","volume":"109","author":"Nicholson","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0030","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bju.15054","article-title":"Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma","volume":"125","author":"Bandini","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0031","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/bju.15177","article-title":"A risk calculator predicting recurrence in lymph node metastatic penile cancer","volume":"126","author":"Bandini","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0032","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/JU.0000000000000746","article-title":"Systematic review and meta-analysis\u2014is there a benefit in using neoadjuvant systemic chemotherapy for locally advanced penile squamous cell carcinoma?","volume":"203","author":"Azizi","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0033","doi-asserted-by":"crossref","first-page":"32212","DOI":"10.18632\/oncotarget.4802","article-title":"Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0034","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1177\/0300060519863546","article-title":"A phase II trial of cabazitaxel as second line chemotherapy in relapsed locally advanced and\/or metastatic carcinoma of the penis","volume":"47","author":"Challapalli","year":"2019","journal-title":"J Int Med Res"},{"key":"10.1016\/j.urolonc.2022.02.014_bib0035","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.euf.2019.05.010","article-title":"The International Penile Advanced Cancer Trial (InPACT): rationale and current status","volume":"5","author":"Canter","year":"2019","journal-title":"Eur Urol Focus"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922000655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922000655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:24:08Z","timestamp":1761042248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922000655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1078143922000655"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.02.014","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of adjuvant chemotherapy compared to neoadjuvant chemotherapy in patients with penile cancer and positive lymph nodes regarding overall survival and free disease survival: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}